TY - JOUR T1 - Improving the Bioavailability and Anticancer Effect of the PCA-1/ALKBH3 Inhibitor HUHS015 Using Sodium Salt JF - In Vivo JO - In Vivo SP - 39 LP - 43 VL - 29 IS - 1 AU - MIYUKI MABUCHI AU - TADASHI SHIMIZU AU - MASAHIRO UEDA AU - YUKA SASAKAWA AU - SYUHEI NAKAO AU - YUKO UEDA AU - AKIO KAWAMURA AU - KAZUTAKE TSUJIKAWA AU - AKITO TANAKA Y1 - 2015/01/01 UR - http://iv.iiarjournals.org/content/29/1/39.abstract N2 - Prostate cancer antigen (PCA)-1/AlkB homologue 3 (ALKBH3) has been identified as a clinically significant factor and siRNA of PCA-1 inhibits DU145 proliferation both in vitro and in vivo. HUHS015 (1), a previous reported PCA-1 small-molecule inhibitor, was also effective without any obvious side-effects or toxicity. The potency of HUHS015, however, is not satisfying. We thought the reason is poor solubility of HUHS015 because insoluble material remained at the injection site after subcutaneous administration. To improve this inhibitor's solubility, we prepared various salts of HUHS015 and examined their solubility, which resulted in the selection of HUHS015 sodium salt (2) for further studies in vivo. Next, we compared the pharmacokinetics of 1 and 2 via several administration routes. We observed significant improvements in the pharmacokinetic parameters. For example, subcutaneous administration of 2 increased the area under the curve (AUC)0-24 by 8-fold compared to 1 and increased the suppressive effect on the proliferation of DU145 cells in a xenograft model. ER -